Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma

BACKGROUND: Hypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular disrupting agent (VDA), mainly affects blood vessels in the central area of the tumor and blocks tubulin polymerization, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min-Young, Shin, Jung-Young, Kim, Jeong-Oh, Son, Kyoung-Hwa, Kim, Yeon Sil, Jung, Chan Kwon, Kang, Jin-Hyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607852/
https://www.ncbi.nlm.nih.gov/pubmed/33143663
http://dx.doi.org/10.1186/s12885-020-07566-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607852/
https://www.ncbi.nlm.nih.gov/pubmed/33143663
http://dx.doi.org/10.1186/s12885-020-07566-x

Ejemplares similares